Impax Laboratories Names Bryan M. Reasons as Chief Financial Officer

Impax Laboratories Names Bryan M. Reasons as Chief Financial Officer

<0> Impax Laboratories, Inc.Mark Donohue, 215-558-4526Sr. Director Investor Relations and Corporate Communications </0>

announced today that Bryan M. Reasons has been appointed senior vice president and chief financial officer (CFO). Mr. Reasons, 45, joined Impax Laboratories in January 2012 as vice president, Finance, and has served as acting CFO since June 2012.

“Following a nationwide search, Bryan Reasons was selected as the best candidate to fill the CFO role,” said Larry Hsu, Ph.D., president and CEO, Impax Laboratories. “He has a breadth of knowledge across accounting and finance, combined with extensive merger and acquisition experience within the pharmaceutical industry. In less than two years, we have significantly transformed Impax’s leadership team across a number of functions as we focus on executing our growth strategy.”

Prior to joining Impax Laboratories, Mr. Reasons served as vice president, Finance, and as vice president, Risk Management and General Auditor, at Cephalon, Inc. (Cephalon), a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (Teva), he served briefly as the vice president, Finance, of Teva. Prior to joining Cephalon in 2005, Mr. Reasons held various finance management positions at Dupont and began his career at PricewaterhouseCoopers LLP, where he held positions of increasing responsibility. He earned a bachelor’s degree in accounting from the Pennsylvania State University and an M.B.A. from Widener University and is a certified public accountant.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: .

Suggested Articles

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.